NEW YORK, Sept. 14, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MAXIMUS, Inc. (NYSE:MMS) from October 30, 2014 through February 3, 2016, inclusive (the “Class Period”) of the important October 6, 2017 lead plaintiff deadline. The lawsuit seeks to recover damages for MAXIMUS investors under the federal securities laws.
To join the MAXIMUS class action, go to http://rosenlegal.com/cases-1184.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) in obtaining the Health Assessment Advisory Service (“HAAS”) contract, MAXIMUS set an unattainable target number of healthcare professionals to recruit and an unattainable target number of assessments; (2) throughout the HAAS contract, MAXIMUS was struggling to recruit, train and ramp-up new health care staff to perform the assessments; (3) the inability to meet its target number of healthcare recruits and target number of assessments, meant MAXIMUS would not earn the performance-based incentive fees from the HAAS contract; and (4) consequently, defendants’ statements about MAXIMUS, its financial condition, and the outlook for its business, including statements about the HAAS contract and the amount of revenue MAXIMUS expected the contract to contribute, lacked a reasonable basis when made. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1184.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 



